Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Belantamab mafodotin
Related studies linked through entity extraction aliases.
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Corneal Findings in Patients Treated With Belantamab Mafodotin
- Status
- TERMINATED
- Phase
- N/A
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE3
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
- Status
- COMPLETED
- Phase
- N/A
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
- Status
- UNKNOWN
- Phase
- N/A
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1